Clinical breast cancer最新文献

{"title":"Effectiveness of Adjuvant Capecitabine in Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Treatment: A Real-World Evidence Study in Korea.","authors":"Min Jeong Kim, Hyo Jung Kim, Ji-Yeon Kim, Junghoon Shin, Yeon Hee Park","doi":"10.1016/j.clbc.2024.12.019","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.019","url":null,"abstract":"<p><strong>Background: </strong>Residual disease after neoadjuvant chemotherapy (NAC) has important role in triple negative breast cancer (TNBC). The CREATE-X study demonstrated a survival benefit from adjuvant capecitabine (adjC) in breast cancer patients, especially for TNBC populations. Because the landscape of early TNBC treatment has been changing rapidly, an optimal adjuvant strategy for real-world practice is needed. We evaluated the effectiveness of adjC in TNBC patients with residual disease after NAC.</p><p><strong>Method: </strong>We used de-identified, anonymous data from an institutional clinical data warehouse to retrospectively analyze 934 TNBC patients who received NAC between 2017 and 2023. Among them, 405 patients received at least 1 cycle of adjC, and 77 received no adjuvant treatment. The primary outcomes of the study were distant-disease free survival (DDFS) rate and overall survival (OS) rate at 3 years. The secondary outcomes were subgroup analyses and Cox regression analyses of survival outcomes.</p><p><strong>Result: </strong>The median follow up period was 34.3 months (range 1.8-71.5). The DDFS rate at 3 years was higher in the capecitabine group: 86.3% of the capecitabine group and 74.4% of the no adjuvant group (P = .019). The OS rates at 3 years were 93.3% and 83.8%, respectively (P = .032). Subgroup analyses indicated a greater benefit from adjC in patients aged 50 years or older and those who received platinum-based NAC, both in terms of DDFS and OS.</p><p><strong>Conclusion: </strong>Our study showed that adjC was more effective than no adjuvant treatment for TNBC patients with residual disease in terms of DDFS and OS.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Added Value of Physical Examination for Breast Cancer Recurrence Detection in Women: A Systematic Review.","authors":"L T H Godding, A Dekker-Klaassen, J H Volders, M van Hezewijk, E J M Siemerink, D van Uden, J Veltman, A H Eijkelboom, S Siesling","doi":"10.1016/j.clbc.2024.12.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.014","url":null,"abstract":"<p><p>As the number of curatively treated breast cancer patients grows and the burden on healthcare increases, effective use of methods to detect recurrences is becoming more important. This systematic review aims to examine the added value of physical examination (PE) in addition to mammography for breast cancer recurrence detection. PubMed, Web of Science, and Scopus were searched. Observational studies including women with a primary diagnosis of invasive or in situ breast cancer without metastases, which reported method of detection for locoregional recurrences (LRRs), and in which PE was defined as examination by a healthcare provider in an asymptomatic patient were included. Quality was assessed using the ROBINS-1 tool. Nine studies were included with data on 14,406 women, 613 LRRs and 349 secondary primary breast cancers. Of the total LRRs, 46.3% were detected by patients, 23.3% by mammography, and 14.8% by PE. PE detected 11% of the LRRs in patients who had breast conserving surgery and 28% of the LRRs in mastectomy patients. PE detected 7.1% of the contralateral breast cancers and 18.8% of ipsilateral lymph node recurrences, compared to 43.9% and 29.2% by mammography. PE detected a LRR in 0.6% of the patients (91/14,406) and mammography in 1.5% of the patients (143/9614). For detection of breast cancer recurrences, PE is of limited added value alongside mammography and self-detection, although it seems more beneficial for mastectomy patients. Further research is required to determine the effectiveness of the most efficient interval for PE across different patient groups.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.","authors":"José P Leone, Ruth Moges, Julieta Leone, Carlos T Vallejo, Heather A Parsons, Michael J Hassett, Nancy U Lin","doi":"10.1016/j.clbc.2025.01.002","DOIUrl":"10.1016/j.clbc.2025.01.002","url":null,"abstract":"<p><strong>Background: </strong>We sought to evaluate prognostic factors in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and their relationship with short- and long-term overall survival (OS).</p><p><strong>Methods: </strong>Using the Surveillance, Epidemiology, and End Results (SEER) database, we evaluated patients with de novo HER2-positive MBC diagnosed from 2010 to 2018. Univariate analyses were performed to determine effect of each variable on OS. Significant variables were included in a multivariate Cox model for OS. Univariate and multivariate logistic regression were used to evaluate the association of each variable with short- (<2 years) and long- (≥5 years) term OS.</p><p><strong>Results: </strong>Overall, 5576 patients were included. Median follow up was 48 months (interquartile range 25-73 months), and median OS was 41 months. The proportion alive at 2, 5, and 8 years was 63.3% (95% confidence interval [CI] 62.0%-64.7%), 37.8% (95% CI, 36.2%-39.4%), and 26.8% (95% CI, 24.8%-28.9%), respectively. Factors associated with short-term OS were older age; Black race; nonductal nonlobular; brain, liver, or lung metastases; estrogen/progesterone receptor (ER/PR)-negative disease, and lower income (all P < .04). Number of metastatic organ sites was not significant. Factors associated with long-term OS were younger age, White race, fewer metastatic organ sites, ER/PR-positive disease, and higher income (all P < .02). Specific organ sites were not significant.</p><p><strong>Conclusions: </strong>In this cohort with de novo HER2-positive MBC, OS improved significantly over the study period. We identified patient-specific and tumor-specific factors that were associated with short- and long-term survival in HER2-positive MBC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes.","authors":"Amir Reza Akbari, Benyamin Alam","doi":"10.1016/j.clbc.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.12.017","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Immediate Breast Reconstruction an Option for Elderly Women? A Comparative Study Between Elderly and Younger Population.","authors":"Julie Marcadet, Caroline Bouche, Carlo Arellano, Elodie Gauroy, Mony Ung, Eva Jouve, Gabrielle Selmes, Marc Soule-Tholy, Thomas Meresse, Carole Massabeau, Ana Cavillon, Charlotte Vaysse","doi":"10.1016/j.clbc.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.01.001","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the incidence of postoperative complications (POC) in elderly patients (EP) compared to younger patients (YP) following immediate breast reconstruction (IBR) after total mastectomy (TM).</p><p><strong>Methods: </strong>This retrospective study included patients treated at the Institut Universitaire of Cancer of Toulouse-Oncopole (IUCT-O) between January 2014 and May 2022. The primary outcome was the incidence of POC within 30 days postoperatively. Secondary outcomes included the delay before initiation of adjuvant treatments and re-hospitalization rates.</p><p><strong>Results: </strong>Elderly patients had a significantly higher rate of POC compared to younger patients, affecting 27.9% of EP and only 14.8% of YP. However, the severity of complications does not differ significantly between YP and EP (69.1% of major POC for YP and 64.7% for EP, P = .6680). Rates of re-hospitalization within 30 days between the 2 groups are similar (67.3% for YP and 61.8% for EP, P = .5962). Most importantly, these complications are not responsible for a delay in initiating adjuvant treatment compared with the younger population. Age ≥ 70 years and obesity (BMI ≥ 30) were identified as independent risk factors for POC.</p><p><strong>Conclusion: </strong>Despite a higher rate of POC, immediate breast reconstruction can be considered for elderly patients, but these patients should be carefully selected and assessed preoperatively to limit the risk of POC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Preoperative Prediction Model Based on Spectral CT to Evaluate Axillary Lymph Node With Macrometastases in Clinical T1/2N0 Invasive Breast Cancer","authors":"Fang Zeng ,&nbsp;Weifeng Cai ,&nbsp;Lin Lin ,&nbsp;Cong Chen ,&nbsp;Xiaoxue Tang ,&nbsp;Zheting Yang ,&nbsp;Yilin Chen ,&nbsp;Lihong Chen ,&nbsp;Lili Chen ,&nbsp;Jing Li ,&nbsp;Suping Chen ,&nbsp;Chuang Wang ,&nbsp;Yunjing Xue","doi":"10.1016/j.clbc.2024.06.010","DOIUrl":"10.1016/j.clbc.2024.06.010","url":null,"abstract":"<div><h3>Objectives</h3><div>To develop a prediction model based on spectral computed tomography<span> (CT) to evaluate axillary lymph node (ALN) with macrometastases in clinical T1/2N0 invasive breast cancer.</span></div></div><div><h3>Methods</h3><div>A total of 217 clinical T1/2N0 invasive breast cancer patients who underwent spectral CT scans were retrospectively enrolled and categorized into a training cohort (n = 151) and validation cohort (n = 66). These patients were classified into ALN nonmacrometastases (stage pN0 or pN0 [i+] or pN1mi) and ALN macrometastases (stage pN1-3) subgroups. The morphologic criteria and quantitative spectral CT parameters of the most suspicious ALN were measured and compared. Least absolute shrinkage and selection operator (Lasso) was used to screen predictive indicators to build a logistic model. The receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to evaluate the models.</div></div><div><h3>Results</h3><div><span>The combined arterial-venous phase spectral CT model yielded the best diagnostic performance in discrimination of ALN nonmacrometastases and ALN macrometastases with the highest AUC (0.963 in the training cohort and 0.945 in validation cohorts). Among single phase spectral CT models, the venous phase spectral CT model showed the best performance (AUC = 0.960 in the training cohort and 0.940 in validation cohorts). There was no significant difference in AUCs among the 3 models (DeLong test, </span><em>P</em> &gt; .05 for each comparison).</div></div><div><h3>Conclusion</h3><div>A Lasso-logistic model that combined morphologic features and quantitative spectral CT parameters based on contrast-enhanced spectral imaging potentially be used as a noninvasive tool for individual preoperative prediction of ALN status in clinical T1/2N0 invasive breast cancers.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e10-e21.e1"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141574921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor of Clinical Breast Cancer, on “Omitting Axillary Lymph Node Dissection is Associated With an Increased Risk of Regional Recurrence in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials” Conducted by Jorge Henrique Cardoso and Collaborators and Published in Clinical Breast Cancer doi.org/10.1016/j.clbc.2024.07.011","authors":"André Mattar ,&nbsp;Francisco Pimentel Cavalcante ,&nbsp;Marcelo Antonini ,&nbsp;Felipe Zerwes ,&nbsp;Eduardo de Camargo Millen ,&nbsp;Fabrício Palermo Brenelli ,&nbsp;Antônio Luiz Frasson ,&nbsp;Lucas Miyake Okumura","doi":"10.1016/j.clbc.2024.08.014","DOIUrl":"10.1016/j.clbc.2024.08.014","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e96-e98"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Breast Cancer Survival Prognosis Through Omic and Non-Omic Data Integration","authors":"Kishaanth Sathyamoorthi,&nbsp;Abishek VP,&nbsp;Lokeswari Y Venkataramana,&nbsp;Venkata Vara Prasad D","doi":"10.1016/j.clbc.2024.08.009","DOIUrl":"10.1016/j.clbc.2024.08.009","url":null,"abstract":"<div><h3>Background and Objective</h3><div>Cancer, the second leading cause of death globally, claimed 685,000 lives among 2.3 million women affected by breast cancer in 2020. Cancer prognosis plays a pivotal role in tailoring treatments and assessing efficacy, emphasizing the need for a comprehensive understanding. The goal is to develop predictive model capable of accurately predicting patient outcomes and guiding personalized treatment strategies, thereby advancing precision medicine in breast cancer care.</div></div><div><h3>Methods</h3><div>This project addresses limitations in current cancer prognosis models by integrating omics and non-omics data. While existing models often neglect crucial omics data like DNA methylation and miRNA, the method utilizes the TCGA dataset to incorporate these data types along with others. Employing mRMR feature selection and CNN models for each type of data for feature extraction, features are stacked and a Random Forest classifier is employed for final prognosis.</div></div><div><h3>Result</h3><div>The proposed method is applied to the dataset to predict whether the patient is a long-time or a short-time survivor. This strategy showcases excellent performance, with an AUC value of 0.873, precision at 0.881, and sensitivity reaching 0.943. With an accuracy rate of 0.861, signaling an improvement of 11.96% compared to prior studies.</div></div><div><h3>Conclusion</h3><div>In conclusion, integrating diverse data with advanced machine learning holds promise for improving breast cancer prognosis. Addressing model limitations and leveraging comprehensive datasets can enhance accuracy, paving the way for better patient care. Further refinement offers potential for significant advancements in cancer prognosis and treatment strategies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 27-37"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding the Article “The Impact of COVID-19 on Breast Cancer Care: A Qualitative Analysis of Surgeons’ Perspectives”","authors":"Akshaya viswanathan,&nbsp;Pitchaipillai Sankar Ganesh,&nbsp;Naji Naseef Pathoor,&nbsp;Rajesh Kanna Gopal","doi":"10.1016/j.clbc.2024.10.015","DOIUrl":"10.1016/j.clbc.2024.10.015","url":null,"abstract":"<div><div>The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article “The Impact of COVID-19 on Breast Cancer Care” and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e100-e102"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of Radiomics and Immune-Related Genes Signatures for Predicting Axillary Lymph Node Metastasis in Breast Cancer","authors":"Xue Li ,&nbsp;Lifeng Yang ,&nbsp;Fa Jiang ,&nbsp;Xiong Jiao","doi":"10.1016/j.clbc.2024.06.014","DOIUrl":"10.1016/j.clbc.2024.06.014","url":null,"abstract":"<div><h3>Background</h3><div><span>To develop a radiogenomics nomogram for predicting </span>axillary lymph node<span> (ALN) metastasis in breast cancer and reveal underlying associations between radiomics features and biological pathways.</span></div></div><div><h3>Materials and methods</h3><div>This study included 1062 breast cancer patients, 90 patients with both DCE-MRI and gene expression data<span>. The optimal immune-related genes and radiomics features associated with ALN metastasis were firstly calculated, and corresponding feature signatures were constructed to further validate their performances in predicting ALN metastasis. The radiogenomics nomogram for predicting the risk of ALN metastasis was established by integrating radiomics signature, immune-related genes (IRG) signature, and critical clinicopathological factors. Gene modules associated with key radiomics features were identified by weighted gene co-expression network analysis (WGCNA) and submitted to functional enrichment analysis. Gene set variation analysis (GSVA) and correlation analysis were performed to investigate the associations between radiomics features and biological pathways.</span></div></div><div><h3>Results</h3><div><span><span>The radiogenomics nomogram showed promising predictive power for predicting ALN metastasis, with AUCs of 0.973 and 0.928 in the training and testing groups, respectively. WGCNA and functional enrichment analysis revealed that gene modules associated with key radiomics features were mainly enriched in breast cancer metastasis-related pathways, such as focal adhesion, ECM-receptor interaction, and </span>cell adhesion molecules. GSVA also identified pathway activities associated with radiomics features such as </span>glycogen synthesis, integration of energy metabolism.</div></div><div><h3>Conclusion</h3><div>The radiogenomics nomogram can serve as an effective tool to predict the risk of ALN metastasis. This study provides further evidence that radiomics phenotypes may be driven by biological pathways related to breast cancer metastasis.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e40-e47.e4"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}